Jul. 30 at 6:16 PM
$CGTX let's acknowledge the elephant in the room: START readout is a long way off and the P3 DLB Pyschosis study will come at a significant cost relative to available cash and MC. That could be bad for SH until mid-2027. However, as others have pointed out, the CNS community is coming around to a "beyond-amyloid" way of thinking and mgmt seemed confident they'll find funding to at least make it to START, or in general get this drug through P3 studies. It's unclear how much dilution that will cost, but the message seems to be "we will find a way to see these trials through." As investors, we have to balance the trial risks (which have been scoped very well IMO), dilution risk, the potential for a catalyst gap, and the possibility that any week they could finally get the partnership deal that zervimesine deserves. I scale my position up and down based on lots of factors, but for all the reasons outlined above, I feel its best to be invested here at least to some degree. So much upside.
